Abeona Therapeutics to Present at Alliance of Regenerative

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Nov 3, 2016 at 8:30 AM

Abeona Therapeutics to Present at Alliance of Regenerative Medicine 4th Annual Advanced Therapies Investor Day in London, UK

NEW YORK, NY and CLEVELAND, OH --(Marketwired - November 03, 2016) - Abeona Therapeutics Inc. ( NASDAQ : ABEO ), a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening rare genetic diseases, today announced that CEO & President, Timothy J. Miller, Ph.D. will be presenting, and joining the Clinical Progress of Gene Therapy Panel, at the Alliance of Regenerative Medicine (ARM) 4^th Annual Advanced Therapies Investor Day in London, UK.

The following are the specific details regarding Abeona Therapeutics Presentation & Panel Discussion:

Event: Alliance of Regenerative Medicine (ARM) Investor Date : Thursday, November 3^rd , 2016 Presentation Time : 1:30 pm UTC Location : London, England Website : http://eu.arminvestorday.com/

Clinical Progress of Gene Therapies Panel Panel Timing: 2:15pm - 3:15pm Speakers Include: Timothy J. Miller, PhD, President & CEO, Abeona Therapeutics Inc. Bernard Gilly, Ph.D., Co-Founder & CEO, GenSight Biologics Sven Kili, M.D., VP & Head of Gene Therapy Development, GlaxoSmithKline Nicolas Koebel, SVP Business Operations, Orchard Therapeutics Silvia Priori, M.D., Professor of Cardiology, University of Pavia

Abeona Recent Highlights:

November 1, 2016: Abeona announced Closing of its Underwritten Offering of Common Stock
October 18, 2016: Abeona received Orphan Drug Designation in The European Union for ABO-102 Gene Therapy in Sanfilippo Syndrome Type A
October 14, 2016: Abeona to presented Top-Line Data of Low-Dose Cohort for ABO-102 in Phase 1/2 Clinical Trial for MPS IIIA Patients at Orphan Drugs and Rare Disease Congress October 19-20th in London, UK
October 7, 2016: Abeona announced Publication of Preclinical Data Supporting Clinical Translation of Juvenile Batten Disease Gene Therapy
October 5, 2016: Abeona announced Data Safety Monitoring Board Approved ABO-102 Dose Escalation for Second Cohort in a Phase 1/2 Clinical Trial for Sanfilippo Syndrome Type A
September 26, 2016: Abeona enrolled First Patient in Phase 2 for EB-101 Gene Therapy Clinical Trial for Epidermolysis Bullosa
September 21, 2016: Abeona announced the exclusive worldwide license of the AIM™ AAV capsid portfolio for next generation gene therapies from University of North Carolina at Chapel Hill
September 8, 2016: Abeona enrolled 5^th Patient in Phase 1/2 Gene Therapy Clinical Trial for Epidermolysis Bullosa

About Abeona: Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing gene and plasma-based therapies for life-threatening rare genetic diseases. Abeona's lead programs are ABO- 102 (AAV-SGSH) and ABO-101 (AAV-NAGLU), adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome (MPS IIIA and IIIB, respectively). Abeona is also developing EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), EB-201 for epidermolysis bullosa (EB), ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JNCL), ABO-202 (AAV-CLN1) gene therapy for treatment of infantile Batten disease (INCL), and ABO-301 (AAV-FANCC) for Fanconi anemia (FA) disorder and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood diseases. In addition, Abeona has a plasma-based protein therapy pipeline, including SDF Alpha™ (alpha-1 protease inhibitor) for inherited COPD, using its proprietary SDF™ (Salt Diafiltration) ethanol-free process. For more information, visit www.abeonatherapeutics.com .

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements are subject to numerous risks and uncertainties, including but not limited to continued interest in our rare disease portfolio, our ability to enroll patients in clinical trials, the impact of competition; the ability to develop our products and technologies; the ability to achieve or obtain necessary regulatory approvals; the impact of changes in the financial markets and global economic conditions; and other risks as may be detailed from time to time in the Company's Annual Reports on Form 10-K and other reports filed by the Company with the Securities and Exchange Commission. The Company undertakes no obligations to make any revisions to the forward-looking statements contained in this release or to update them to reflect events or circumstances occurring after the date of this release, whether as a result of new information, future developments or otherwise.

Investor Contact: Christine Berni-Silverstein Vice President, Investor Relations Abeona Therapeutics Inc. +1 (212)-786-6212 csilverstein@abeonatherapeutics.com Media Contact: Andre'a Lucca Vice President, Communications & Operations Abeona Therapeutics Inc. +1 (212)-786-6208 alucca@abeonatherapeutics.com

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

U.S. Gold Corp. Gears Up for Key October Event

Marking Calendars for the Emerging Growth Showdown There's nothing quite like the buzz leading up to an event where you know someone’s either gonna make a splash or barely leave a ripple. U.S. Gold Corp. is drawing some attention ahead of the Emerging Growth Conference on October 29, 2026. This ain't just any corporate dog-and-pony show—it's a chance for the Gold...

Firmable Climbs G2 Ranks in Sales Intelligence

Success stories aren't written overnight, and Firmable's recent leap in G2's rankings proves that point. This AI-native B2B sales powerhouse has muscled its way from #8 to #4 on the global Momentum Grid for Sales Intelligence, marking a dramatic rise that's hard to ignore. Being recognized at this level shows the company's on a solid path, but let's see what makes this...

North Island Credit Union Eases Student Access to Banking

Breaking Down Barriers with Student Banking Services Stumble into any financial setup these days, and you'll hear the same refrain: young people need more access to banking. North Island Credit Union seems to have taken that idea to heart, landing a national Bank On certification for their Student Checking account. It ain't just any badge; it's the mark of reliability,...

Gargle App Elevates Dental Marketing Transparency, ROI Focus

Dentists Finally See the Whole Picture with Gargle's App Out in Lehi, Utah, there's a little tech shakeup courtesy of Gargle—a name some might squint at if they haven't been following dental-focused digital marketing. Now, with their latest move, the Gargle App, we're talking about pulling back the curtain and giving dental practices a clear view of their marketing...

Enertech's New Moves Aim to Make Geothermal Mainstream

Breaking Through Financial Barriers in Geothermal Energy Finally, we're seeing some real movement in the geothermal heat pump sector. The longtime hurdles that kept ground-sourced heating and cooling tech at arm's length from the everyday homeowner are starting to tumble, thanks to Enertech Global's latest initiatives. Enertech's Double Deal: A New Lease on Geothermal...

Northeast Indiana Bancorp Shows Solid Third Quarter Gains

Holding Steady in a Shaky Market In a market often rocked by turbulence, it seems Northeast Indiana Bancorp, Inc. has found a decent footing to stand on. Announcing their third-quarter results for 2026, they’ve posted net income of $1.991 million, showcasing a neat jump from the $1.793 million in the same period last year. Not bad at all for the parent company of First...

Valmet's Strategic Moves and Financial Gains Explained

Valmet's Strategic Playbook for Growth Anyone keeping tabs on Valmet's recent parade of press releases knows they're on a darn aggressive growth spurt. Talk about shaking things up with a firm grip on the paper and forest products sector and beyond. Their interim review from January to September 2026 spells it out with strong orders received and a solid increase in...

New Research Awards Target Drug Resistance in Cancers

Well, this is a breath of fresh air in the lung cancer scene, let's talk about some promising news for those battling RET-positive cancers. The LUNGevity Foundation and RETpositive have handed out some well-deserved awards to researchers aiming to crack the stubborn nut of drug resistance in RET-positive cancer therapies. Changing the Game for RET-positive Cancer RET gene...

Technical Deep Dive into HONOR X9e Pro's Durability

Rethinking Smartphone Power HONOR's latest device, the X9e Pro, flaunts an 11,000mAh battery—stuck it right behind a neat cover without making the thing feel like a brick. You'd think with a battery that big, they’d have to hire bodybuilders to lift it, but nope. At 8.08mm thick and weighing just 203g, this phone bucks the bulk. They’ve squeezed the power of a power...

MetroScape: Local Roots Fuel Bold DFW Growth Plans

A Local Business with Big Aspirations Here's the deal, folks: Local guys Dr. Marc Nickell and Chris Brewer snatched up MetroScape Landscape like it was the last slice of grandma's pie. Why? Not just for the greenbacks—they're putting down roots in their very own backyard, the Dallas-Fort Worth area. What Does Local Really Mean? Look, it's one thing hitting up a...